A
Alexandra Langendorfer
Researcher at Merck & Co.
Publications - 17
Citations - 7215
Alexandra Langendorfer is an academic researcher from Merck & Co.. The author has contributed to research in topics: Lovastatin & Unstable angina. The author has an hindex of 15, co-authored 17 publications receiving 7090 citations. Previous affiliations of Alexandra Langendorfer include University of North Texas Health Science Center.
Papers
More filters
Journal ArticleDOI
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Antonio M. Gotto,Edwin J. Whitney,Evan A. Stein,Deborah R. Shapiro,Michael Clearfield,Stephen E. Weis,Jesse Y. Jou,Alexandra Langendorfer,Polly A. Beere,Douglas J. Watson,John R. Downs,John S. de Cani +11 more
TL;DR: People with average TC and LDL-C levels and below-average HDL-C may obtain significant clinical benefit from primary-prevention lipid modification, and on-treatment apoB, especially when combined with apoAI to form the apOB/AI ratio, may be a more accurate predictor than LDL- C of risk for first AMCE.
Journal ArticleDOI
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.
Reagan H. Bradford,Charles L. Shear,Athanassios N. Chremos,Carlos A. Dujovne,Maria Downton,Frank A. Franklin,A. Lawrence Gould,Michael Hesney,Jim Higgins,Dennis P. Hurley,Alexandra Langendorfer,David T. Nash,James L. Pool,Harold W. Schnaper +13 more
TL;DR: In the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, the efficacy and safety of lovastatin were evaluated in 8245 patients with moderate hypercholesterolemia.
Journal ArticleDOI
Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatin
John R. Downs,Michael Clearfield,H.Alfred Tyroler,Edwin J. Whitney,William Kruyer,Alexandra Langendorfer,Vladimir Zagrebelsky,Stephen E. Weis,Deborah R. Shapiro,Polly A. Beere,Antonio M. Gotto +10 more
TL;DR: Treatment with lovastatin 20 to 40 mg daily for primary prevention of coronary heart disease was well tolerated and reduced the risk of first acute coronary events without increasing the riskof either noncardiovascular mortality or cancer.
Journal ArticleDOI
Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
Reagan H. Bradford,Charles L. Shear,Athanassios N. Chremos,Carlos A. Dujovne,Frank A. Franklin,Ruth B. Grillo,Jim Higgins,Alexandra Langendorfer,David T. Nash,James L. Pool,Harold W. Schnaper +10 more
TL;DR: It is indicated that lovastatin maintains its efficacy over long-term follow-up, particularly in effectively lowering LDL cholesterol, is generally well tolerated, and has a favorable safety profile.